Compare RDW & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDW | SVRA |
|---|---|---|
| Founded | 2020 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | N/A | N/A |
| Metric | RDW | SVRA |
|---|---|---|
| Price | $7.89 | $5.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $12.67 | $7.33 |
| AVG Volume (30 Days) | ★ 35.4M | 1.4M |
| Earning Date | 03-09-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $296,147,000.00 | N/A |
| Revenue This Year | $9.16 | N/A |
| Revenue Next Year | $40.24 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.87 | $1.89 |
| 52 Week High | $26.66 | $7.01 |
| Indicator | RDW | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 39.91 | 53.79 |
| Support Level | $8.65 | $5.10 |
| Resistance Level | $10.40 | $5.44 |
| Average True Range (ATR) | 1.36 | 0.33 |
| MACD | -0.51 | -0.00 |
| Stochastic Oscillator | 1.26 | 78.02 |
Redwire Corp is engaged in mission-critical space solutions and reliable components for the next-generation space economy. It assists its customers in solving the complex challenges of future space missions and industries. The company's space infrastructure offerings include a broad array of modern products and services, which have been enabling space missions. The company's plan enables it to combine decades of flight heritage with a culture creating new technologies that are the building blocks of space infrastructure for government and commercial customers.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.